Navigation Links
New Report Provides Insight Into Developments in the Market for Anxiety and Depression Therapies
Date:10/16/2007

SCOTTSDALE, Ariz., Oct. 16 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for anxiety and depression therapies.

In this report, entitled "MedPredict Thought Leader Insight & Analysis: Anxiety & Depression," physician experts from North America and Europe discuss the strengths and weaknesses of a variety of branded and near-market antidepressants and anxiolytics.

"There have been some notable developments in the use of antipsychotics, and special emphasis on new classes -- including CRF and NK antagonists," according to Jeff Berk, MedPredict President. "The thesis of this panel is that there are two types of new drug launches that will be successful in the next five years. The first is augmentation strategies to SSRIs. Today this includes the use of low dose quetiapine. This time frame should also see the approval of the first NK and CRF antagonists." According to this report, monotherapy strategies will find a home mostly in the primary care setting after failure of a generic SSRI. In the community setting, safety will trump efficacy, and a parity claim with an improved side effect profile will win out.

The report also discusses the role of genomics, endophenotypes and biomarkers in the development of pharmacotherapies for depression.

Drugs/Companies mentioned in this report include: Effexor (venlafaxine; Wyeth), Lexapro (escitalopram; Forest), Pristiq (o-desmethylvenlafaxine; Wyeth), Cymbalta (duloxetine; Lilly), Wellbutrin (bupropion; GlaxoSmithKline), Valdoxan (agomelatine; Novartis/Servier), bifeprunox (Wyeth/Solvay/ Lundbeck), Seroquel (quietiapine; AstraZeneca), amibegron (Sanofi-Aventis), GSK-561679 (GSK), Pexacerfont (BMS-562086; Bristol-Myers Squibb), ONO-2333Ms (Ono), casopitant (GlaxoSmithKline), saredutant (Sanofi-Aventis), esmirtazapine (Organon / Schering-Plough), Nemifitide (Tetragenix), SSR241586 (Sanofi-Aventis), and many others.

This report can be purchased by contacting MedPredict. Members of the media may request an interview.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. No harm in reducing prenatal check up to 3 - 6 times says WHO report
2. Autopsy reports could be valuable and informative
3. China reports declining number of SARS Cases
4. Russia Reports First SARS Case
5. Report on the Safety and Effectiveness of Melatonin supplements
6. WHO report asks for improved healthcare for mother and child
7. Research reports that c-section deliveries are rising
8. Jharkhand reports 13,000 Malaria cases
9. Sepsis Death Reported With Mifepristone – FDA Issues Warnin
10. Experts Insist That Neonatal Herpes Be Reported Regularly
11. Uganda Reports Failure To Contain Sleeping Sickness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... , ... Afrimesure specializes in providing clients with ideal measurement ... HVAC facilities. Their knowledgeable staff also takes care of the installation, IQ/OQ/PQ qualification ... a variety of MadgeTech systems available for sterilization and temperature monitoring, including the ...
(Date:5/25/2016)... ... May 25, 2016 , ... The University of San Francisco (USF) has named ... lead a team of more than 100 full-time faculty and staff, and serve as ... in late August. , Baker comes to USF from the University of Washington in ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... "FCPX LUT ... quality of your footage," said Christina Austin - CEO of Pixel Film Studios. ... can quickly and easily add stylish color grades to their footage. A LUT is ...
(Date:5/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... as the Medical Director of its new DeSoto facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:5/24/2016)... Angeles, CA (PRWEB) , ... May 24, 2016 , ... ... study found that a group of people randomly assigned to reduce the amount of ... experienced a 12 percent drop in body weight enjoyed better sleep, improved quality of ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... , May 23, 2016 ... for the treatment of cancer and orphan genetic diseases, ... up to $4.4 million from the Israel Innovation Authority ... Israeli Ministry of Economy and Industry. The mission of ... entrepreneurship in various industries, including science and technology, while ...
(Date:5/23/2016)... Conn. , May 23, 2016   ... has entered into an agreement with Egalet Corporation ... patent claims. As part of the agreement the ... and will enable all three companies to develop ... properties. "This agreement reflects the commitment ...
(Date:5/20/2016)... India , May 20, 2016 ... Survey Report 2016 to Medical Devices of its ... and in-depth survey on the current state of ... overview of the industry like definitions, classifications, Specifications, ... information about manufacturing process like Raw Material Suppliers, ...
Breaking Medicine Technology: